Avances enartritis reumatoide
147
44. Colmegna, I.; Pryshche
penedERKSignaling
in Hematopoietic Pr
Immunol143, 73-‐82
(2012). Disponibleen:
.
45. Van Boxel, J. A.; Pag
rheumatoid synovial
membranes. NEngl J
46. Edwards, J. C.; Cambridge, G.; Abrahams, V.M. Do self-‐perpetuating B lymphocytes drive
humanautoimmunedisease? Immunology97, 188-‐196(1999).
47. Astry, B.; Harberts, E.; Moudgil, K. D. A Cytokine-‐Centric View of the Pathogenesis and
Treatment of Autoimmune Arthritis. J Interferon Cytokine Res 31, 927-‐940 (2011).
Disponibleen:http://dx.doi.org/10.1089/jir.2011.0094.
48. Sánchez-‐Ramón, S.; López-‐Longo, F. J.; Carreño, L. Interleucinas en la fisiopatología de la
artritis reumatoide: más allá de las citocinas proinflamatorias. Reumatol Clin 6(S3), S20–
S24(2011).
49. Kazuo Okamoto, K.; Takayanagi, H. Regulation of bone by the adaptive i
arthritis.
Arthritis Res Ther13,
219 (2011).
Disponible en
‐
research.com/content/13/3/219.
50. Arboleya, L.; Castañeda, S. Osteoinmunología: el estudio de la relación
inmuneyel tejidoóseo. ReumatolClin9, 303-‐315(2013).
51. Hamilton, J. A.; Tak, P. P. The dynamics ofmacrophage lineage populations ininflammatory
andautoimmunediseases. ArthritisRheum60, 1210-‐1221(2009).
52. Chang, S.K; Gu, Z.; Brenner, M. B. Fibroblast-‐like synoviocytes in inflammatory arthritis
pathology: theemerging roleof cadherin-‐11. Immunol Rev233,256-‐266(2010).
53. Hueber, A. J.; Asquith, D. L.;Miller, A.M.; Reilly, J.; Kerr, S.; Leipe, J.; et al.Mast cells express
IL-‐17A inrheumatoidarthritis synovium. J Immunol 184, 3336-‐3340(2010).
54. Dieguez-‐Gonzalez, R.; Calaza, M.; Perez-‐Pampin, E.; Balsa, A.; Blanco, F. J.; Canete, J. D;et al.
Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-‐kappaB and the neighbor
intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther11,R42
(2009).
55.
tural Killer Cells and Their Role in Rheumatoid
ific World Journal 2012.
Disponible en:
56.
une responses by interleukin-‐27. Immunol Rev
57. Stack, R.J.; Sah
complexes at the earliest phases of
rheumatoid ar
literature. Arthritis Care Res 2013.
Disponibleen:
58. Ek, M.; Engbl
bsson, P. J.; Ericsson-‐Dahlstrand, A.
Inflammatory
d-‐brain barrier. Nature 410, 430-‐
431(2001).
59. Moreland, L. W.; Genovese, M. C.; Sato, R.; Singh, A. Effect of etanercept on fatigue in
patients with recent or established rheumatoid arthritis. Arthritis Rheum 55, 287-‐293
(2006).
60. Kuriya, B.; Villeneuve, E.; Bombardier, C. Diagnostic and prognostic value of history-‐taking
and physical examination in undifferentiated peripheral inflammatory arthritis: a
systematic review. JRheumatol Suppl, 87, 10-‐14(2011).
61. Arnett, F. C.; Edworthy, S. M.; Bloch, D. A.;McShane, D. J.; Fries, J. F.; Cooper, N. S.; et al. The
American Rheumatism Association 1987 revised criteria for the classification of
rheumatoidarthritis. ArthritisRheum31, 315-‐324(1988).
62. Harrison, B. J.; Symmons, D. P.; Barrett, E.M.; Silman, A. J. Theperformanceof the1987ARA
classification criteria for rheumatoid arthritis in a population based cohort of patients
with early inflammatory polyarthritis. American RheumatismAssociation.J Rheumatol25,
2324-‐2330(1998).
63. Finckh, A.; Liang, M.H.; van Herckenrode, C.M.; de Pablo, P. Long-‐term impact of early
treatment on radiographic progression in rheumatoid arthritis: Ameta-‐analysis. Arthritis
Rheum55, 864-‐872(2006).
64. Schneider, M.; Krüger K. Rheumatoid arthritis—early diagnosis and diseasemanagement.
DtschArztebl Int 110, 477-‐484(2013).
